Almost all nucleated cells secrete extracellular vesicles (EVs) that are heterogeneous spheroid patterned or round shape particles ranging from 30 to 200 nm in size. Recent preclinical and clinical studies have shown that endothelial progenitor cell-derived EVs (EPC-EVs) have a beneficial therapeutic effect in various diseases, including cardiovascular diseases and kidney, and lung disorders. Moreover, some animal studies have shown that EPC-EVs selectively accumulate at the injury site with a specific mechanism of binding along with angiogenic and restorative effects that are superior to those of their ancestors. This review article highlights current advances in the biogenesis, delivery route, and long-term storage methods of EPC-EVs and their favorable effects such as anti-inflammatory, angiogenic, and tissue protection in various diseases. Finally, we review the possibility of therapeutic application of EPC-EVs in the clinic.

Keywords: extracellular vesicles, endothelial progenitor cells, exosomes, miR (microRNA), clinical application of EPC exosomes

INTRODUCTION

Endothelial progenitor cells (EPCs) have been widely used to treat cardiovascular ischemic diseases since their discovery in 1997 (1). Initial clinical trials, in parallel with preclinical studies, raised hopes of cures for life-threatening ischemic diseases (2). In subsequent studies, EPC biology was further investigated and it was found that after long-term culture of between 15 and 21 days, cobblestone-shaped colonies emerged, called blood endothelial outgrowth cells (3). The phenotypes of these cells are similar to those of the adult endothelial cells and have a greater proliferative rate (3); Yoder’s group (4) found similar cells from umbilical cord blood cells (4). Clinical studies have demonstrated that the origin of EPC is bone marrow, and considering pathological triggers, these cells migrate to damaged tissues and physically contribute to facilitating vasculature (3, 5–7). However, several groups are concerned about the existence of EPCs based on mouse data (8). In addition, the culture of EPCs in diverse systems, different methodologies, and various “misleading terms” has led to confusion in EPC biology and application. To this end, a recent consensus attempted to standardize EPC nomenclature based on cellular phenotypes and biological functions (9). A consensus statement on EPC nomenclature and culture standardization may facilitate progress toward the use of EPC-derived extracellular vesicle (EPC-EV) therapy. Depending on the sequence of appearance in culture, Hur et al. (10) reported two types of EPCs. The first were termed early EPCs or myeloid angiogenic cells that were positive for CD45, CD14, and
mainly worked via paracrine mechanisms, such as growth factors and EVs (10, 11). The second cell population, named late-EPC or endothelial colony-forming cells (ECFCs), usually appeared in culture at 2 to 3 weeks after cell culturing, and had similar phenotypes as endothelial cells, and enhanced neovascularization in ischemic tissues (10, 12). Recent studies have demonstrated that ECFCs secrete EVs that are crucial for organ restoration (13–15).

Almost all nucleated cells secrete extracellular vesicles cargo which delivers nucleic acid and proteins to the recipient cells. The International Society for Extracellular Vesicles consensus recommendation on nomenclature endorses to use “extracellular vesicles” as a generic term for a lipid bilayer particle released from the cell and cannot replicate. Moreover, it has a broader meaning which can cover subtypes like exosomes and microvesicles as well. Depending on the physical size range, EVs divide small (<100 nm), medium (<200 nm), or large (>200 nm), and usually express CD63+, CD81+, Annexin A5, etc., surface markers (16). The small EVs are generated within endosomes as intraluminal vesicles and this complex EVs biogenesis occurs by endosomal sorting complex required for transport (ESCRT) sorting machineries involvement (17). Whereas, medium or large EVs originate by an outward budding at the plasma membrane (Figure 1) (18). There are several methods to isolate secreted EVs such as classical differential centrifugation, density gradient centrifugation, size-exclusion chromatography, ultrafiltration, immunocapture, precipitation, and tangential flow filtration, etc. (Figure 1) (16). Each EV isolation strategy or its working principle along with their advantages and disadvantages was reviewed previously (19).

A seminal study showed that EPCs secrete microvesicles, and the latter activate an angiogenic program in endothelial cells via horizontal transfer of mRNA (20). Subsequently, preclinical studies showed that EPC-EVs have superior therapeutic effects on various ischemic diseases (Figure 2) (21–23). In the last decade, numerous studies on EPC-EVs have shed light on EV biogenesis, uptake, and mechanism of action (24–27). This review highlights recent advances in the biogenesis, biological functions, route of delivery, and long-term storage of EPC-EVs. Finally, we describe potential translation to the clinic and regions of application in the context of various ischemic and inflammatory diseases.

EPCs VS. EPC-EVs

Recently, it has been reported that therapeutic cell transplantation-related effects for cardiovascular diseases are a result of paracrine mechanisms and not from direct cell contribution to damaged organs (28). Regardless of the target delivery technique, the long-term engraftment of cells is limited; hence, the striking short-term improvement in ischemic organ function after cell transplantation is mainly associated with paracrine trophic factors such as EVs (29). It has been shown that early EPC populations are contaminated with hematopoietic cell subsets, such as monocytes (30), and the latter secrete various nanoparticles. In contrast, late EPCs have specific phenotypes and biological functions similar to endothelial cells, and secrete angiomiRs-shuttled EVs, which are a key genetic material for neovascularization of ischemic tissues (14, 31, 32). Dozens of preclinical studies have demonstrated EPC-EV effects that are superior to those of the ancestor (33). EVs possess numerous advantages over cell-based therapies in the context of regenerative medicine in terms of (1) cargo delivery of various favorable miRs responsible for angiogenesis, fibrosis, and cell proliferation; (2) potential for “off the shelf” availability and respective for repetitive transplantation; (3) cell-free biological products that may be utilized as drug carrier systems in the pharmaceutical industry, and finally (4) generally reduced immunogenicity owing to which allogenic transplantation is an additional benefit. The abovementioned benefits are crucial for treating either acute or chronic diseases. The latter listed major advantages of the EVs are linked to less immunogenic than their parental cells because of the lower abundance of transmembrane proteins such as MHC complexes on their surface (34). Unlike live cells, EVs have a long shelf life and may be transported and stored for long periods (see the section on long-term preservation and storage of EVs). In the representative Venn diagram (Figure 3) (transcriptome data from previous publication PMID: 28631889), we summarize the similarities and differences between ECFC-derived microRNAs (miRs) and ECFC-EV-derived miRs (35). It can be clearly seen that the majority of parent cell-derived miRs (ECFC-miRs) can be found in ECFC-EV-derived miRs, suggesting a similar transcriptome profile along with the mechanism of action (Figure 3). A previous study showed that the therapeutic potential of EPC-EVs is superior in terms of enhancing neovascularization and recovery in a murine hind limb ischemia model (12). The mechanism of activation of the angiogenic program in quiescent endothelial cells is linked by horizontal transfer of genetic materials such as angiomiR, RNA, and proteins (12, 13). Of note, ischemia itself is a trigger for angiogenesis. However, angiogenesis-qualified angiomiRs accelerate not only angiogenesis but also proliferative and anti-apoptotic effects (Figure 4). Collectively, well-packed EPC-EVs have a great advantage in preserving ischemic tissue from injury, and future studies are warranted to define the beneficial effects of EPC-EVs.

EPC-EVS IN CARDIOVASCULAR DISEASES

Cardiovascular diseases are the leading cause of mortality and morbidity in the globe (36). It has been shown that therapeutic neoangiogenesis with EPCs is a promising strategy for treating advanced cardiovascular diseases and preventing major adverse events (37). Similar transcriptome profiles of EPC-derived EVs to the EPCs facilitate therapeutic application EPC-EVs in CVD. Yue et al. (38) demonstrated that EPC-derived exosome treatment enhanced left ventricle cardiac function, reduced cell apoptosis, diminished myocardial scar size, and promoted post-myocardial infarction neovascularization. Previous studies have shown that sonic hedgehog modified progenitor cells (CD34+) actively secrete exosome cargo and carry various reparative molecules to cure the ischemic myocardium (39, 40). EPC-EVs regulate cardioprotection by
orchestrating cell angiogenesis, migration and adhesion, cell proliferation, and cell differentiation processes (Figure 5). Target gene expression analysis of EPC-EV-derived miR revealed that heart regeneration and protection enriched functional gene upregulation (Figure 5). Cardioprotective properties of EPC-derived EV is associated with miR-218-5p and miR-363-3p overexpression. The latter facilitated cardiac function via enhanced neoangiogenesis and inhibited myocardial fibrosis (41). Moreover, EPC-EVs treatment promoted mesenchymal-endothelial transition and along with protective effect to myocardial infarcted tissues (42). Recently, Chen et al. (33) showed that using EPC-EVs and encapsulation with a hydrogel could increase biological activity for up to 3 weeks through sustained release. Furthermore, the injected hydrogel system for sustained EPC-EV delivery into the ischemic myocardium augmented hemodynamics via increased vessel density in the peri-infarcted area along with reduction in myocardial scar formation. Interestingly, the regenerative efficacy of hydrogen-encapsulated EPC-EVs is not inferior to that of the parent cells or EPCs (33). Repetitive systemic transplantation of EVs is a simple delivery option. We have recently shown that systemic repetitive transplantation of EVs derived from regeneration-associated cells in a rat model of myocardial IR injury significantly enhanced cardiac functions, such as ejection fraction, and preserved mitral regurgitation. In addition, we could not observe anti-donor immune responses even when EV transplantation was performed in allogeneic settings.

Taken together, EPC-EVs have anti-inflammatory and anti-fibrotic properties and may enhance angiogenesis in the ischemic myocardium.

EPC-EVS IN ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME (ALI/ARDS) PATHOLOGY

Systematic reviews have demonstrated that the mortality rate in ALI/ARDS is between 36 and 44% and is usually induced by various etiologies such as sepsis, pneumonia, and severe traumas (43). The high mortality rate in ALI/ARDS facilitates various “cell-free” therapeutic EVs, including EPC-EVs. Emerging data shows that EPC-EV administration markedly reduced lipopolysaccharide-induced lung inflammation compared to that in the control groups, indicating a strong anti-inflammatory
effect of EVs. Histological examination of the EPC-EV-administered group showed limited alveolar edema and lung neutrophil infiltration, and reduced cytokine/chemokine levels in the bronchoalveolar lavage fluid (44). Mechanistically, EPC-EV contains abundant miRNA-126, and overexpression of miRNA-126-3p can target phosphoinositide-3-kinase regulatory subunit 2, whereas overexpression of miRNA-126-5p inhibits the inflammatory alarmin high mobility group box 1 (HMGB1) and the permeability factor vascular endothelial growth factor (VEGF) α (44). Wu et al. (45) reported different mechanistic insights into EPC exosome-mediated transfer of miR-126 to endothelial cells such as the selective expression of SPRED1 and the enhancement of RAF/ERK signaling pathways that were primarily responsible for restoring the acute-injured lung. In summary, EPC-EVs have a beneficial effect in improving ALI/ARDS outcomes, and further studies are necessary to define optimal and targeted EV delivery methods to the site of injury.

**EPC-EVS IN SEPSIS**

Sepsis is a systemic inflammation induced mainly by microorganisms, leading to organ dysfunction. Recent studies have highlighted that EPC transplantation has a beneficial effect on animal models of sepsis (46, 47). Mechanistically, various pro-inflammatory cytokines induced by pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) in peripheral blood cause vascular injury and increase permeability (47). Consequently, in response to vascular injury, EPCs mobilize in an SDF1α-dependent manner and directly recruit to the injury site and differentiate into mature endothelial cells (47, 48). Fan et al. (46) demonstrated that EPCs and SDF1α administration synergistically improves survival in septic animals via enhanced miR-126 and miR-125b expression, which is believed to play key roles in the maintenance of endothelial cell function and inflammation. Later, they demonstrated that the protective effect of EPCs on the microvasculature after sepsis occurs via exosome-mediated transfer of miRs such as miR-126-3p and 5p (49). EPC-EVs miR-126-5p and 3p suppressed DAMP-induced HMGB1 and vascular cell adhesion molecule 1 (VCAM1) levels, whereas inhibition of miR-126-5p and 3p through transfection with miR-126-5p and 3p inhibitors disrupted the beneficial effect of EPC exosomes. Thus, EPC-EVs prevent adverse septic complications via miR-126 delivery (49).
EPC-EVS IN ACUTE KIDNEY DISEASES

Ischemia/reperfusion is a major cause of acute kidney injury (AKI) in humans, and is associated with tubular cell necrosis and endothelial cell dysfunction or loss. Growing evidence has shown that the therapeutic potential of EPC-EVs is superior in terms of acute kidney disease. Vinas et al. (15) used ECFC-derived EVs in an acute kidney injury mouse model and showed that miR-486-5p enriched ECFC exosomes significantly reduced ischemia-induced kidney injury. Histologically, exosome treatment decreased the infiltration of neutrophils along with diminished apoptosis and caspase-3 activation. Moreover, administration of exosomes to acute kidney injury-induced animals caused potent protection against kidney injury after 24 h, as evidenced by normalization of plasma creatinine and blood urea nitrogen to the same level as that in the healthy control. Mechanistically, miR-486-5p enriched ECFC exosomes target to reduce the phosphatase and tensin homolog, and stimulate the Akt phosphorylation pathway for ischemic tissue preservation (15). Cantaluppi et al. (13) demonstrated that EPC-EVs carrying miR-126 and miR-296 protect against experimental acute renal IRI, as evidenced by a significant decrease in serum creatinine and blood urea nitrogen levels and improvement in histological signs of microvascular and tubular injury. It is well-known that EPC-EVs exert miR-126 and have strong angiogenic and anti-apoptotic potential (23). In another study, EPC-EV transplantation rescued an experimental model of anti-Thy1.1-induced glomerulonephritis via inhibition of antibody- and complement-mediated injury of mesangial cells (50). In a review article, Sun et al. (51) summarized that stem/progenitor cell-derived EVs, including EPC-EVs, have beneficial effects such as anti-inflammatory, anti-apoptotic, anti-fibrotic, and may also promote renal cancer progression. In summary, EPC-EVs were shown to have a strong renoprotective effect in an acute kidney injury model, and future studies are warranted to extend their application to chronic kidney diseases.

EPC-EVS IN BONE AND CONNECTIVE TISSUE REPAIR

Accumulating evidence demonstrates that EPCs have beneficial effects on bone regeneration by secreting trophic and paracrine factors (52, 53). Pang et al. (54) showed that EPCs modulate the survival, migration, and differentiation potential of osteoclast precursors through the VEGFR-2, CXCR4, Smad2/3, Akt, ERK1, and p38 MAPK pathways (Figure 6). Interestingly, target genes of highly expressed EPC-EV miRs yielded several significant bone
FIGURE 4 | As shown in the flow chart that highly expressed ECFC-EC-derived miRs biological targets were predicted in silico. The most significantly enriched functional annotation were Angiogenesis, vasculogenesis, and lymphangiogenesis. This miR sequence data was generated from PMID: 28631889. MicroRNA target genes were predicted using IPA with information from TargetScan, miRecords, and TarBase databases.

FIGURE 5 | Flow chart depicts highly expressed ECFC-EC-derived miRs biological targets that were predicted in silico. The significantly enriched functional annotation was associated with heart tissue repair. This miR sequence data was generated from PMID: 28631889. MicroRNA target genes were predicted using IPA with information from TargetScan, miRecords, and TarBase databases.
and osteoblast differentiation-enriched functional categories (Figure 7). Through in silico experiments, Qin et al. (55) showed that EPC-EVs regulate the osteoblastic differentiation of bone marrow-derived mesenchymal stromal cells by inhibiting the expression of osteogenic genes and increasing proliferation. This suggests that EPC-EVs are able to control osteogenesis and have beneficial effects on connective tissue development, such as fibroblasts and chondrocytes (Figure 7). A preclinical study showed that EPC-EVs have a strong therapeutic effect on distraction osteogenesis by stimulating angiogenesis and osteogenesis (56). The aforementioned therapeutic advantage of EPC-EVs in bone and connective tissue regeneration expands its application to cure various skeletal muscle diseases.

**ANGIOGENIC PROPERTIES OF EPC-EVS**

Recent studies have shed light on the biological activity and function of EPC-Ev-derived miRs in various in vitro and in vivo models. Dellet et al. (35) demonstrated the high expression levels of 15 miRs identified in ECFC and ECFC-derived EVs such as miR-10a/b, miR-21-5p, miR-30a-5p, miR-126-5p, let-7 families, and miR151a-3p. Through systematic investigation of the biological activity of EV-derived miRs, we comprehensively analyzed the translation of EPC-Evs from the bench to the bedside. This approach has the potential to be an important source of new therapeutic strategies for the treatment of a variety of diseases, including cardiovascular diseases, where cell migration and proliferation are crucial factors. The development of therapeutic strategies based on EVs is a promising field of research, and further investigation is needed to fully exploit the potential of EV-based therapies.
TABLE 1 | EPC-derived angi-o-miR.

| miRs     | Mechanism of action                       | Target diseases                                                                 | EVs or Exo origin | Ref # |
|----------|-------------------------------------------|---------------------------------------------------------------------------------|-------------------|-------|
| miR-126-3p | VEGF-A, IL-1, IL-6, IGF-1, ANG1, ANG2, and SPRED1 | Enhanced biological function of EPC from patients with ICM. Knocking down miR-126-3p from EPC abolished their angiogenic activity | EPC-derived EVs   | (23, 57) |
| miR-126-5p | DLK1                                      | Prevents atherosclerotic lesion formation via DLK1 suppression                   | EC                | (35, 58) |
| miR-10b   | VEGF and HOX                              | Promotes tumor growth via enhanced angiogenesis                                  | Circulating EPC, EC | (35, 59, 60) |
| let-7b    | Proangiogenic paracrine factors and IL-10 and IL-12 | EGFC-derived EVs vastly contain various let-7 miR and modulate ischemia-induced angiogenesis. Tumor-associated macrophages phenotypes were changed upon downregulation | ECFC              | (35, 61–64) |
| let-7i-2-5p |                                         |                                                                                 |                   |       |
| let-7i-1-5p |                                         |                                                                                 |                   |       |
| let-7i-5p  |                                         |                                                                                 |                   |       |
| miR-486-5p | PTEN and Akt pathway                      | Delivery of ECFC exosomes reduces ischemic kidney injury via transfer of miR-486-5p targeting PTEN | ECFC              | (15, 35) |
| miR-296-5p | HGS, VEGF, PI3K, and inhibiting DLL4 and Notch1 | Augmented primary human brain microvascular endothelial cells angiogenic property | Angiogenic EC      | (65)   |
| miR-150   | c-Myb                                     | MIR-150 significantly promoted the migration and tube formation ability of EPCs in vitro and enhanced EPCs homing, organization, and resolution ability in vivo | EPC               | (66)   |

EPC, endothelial progenitor cells; Exo, exosomes; EC, endothelial cells; ECFC, endothelial colony-forming cells; ICM, ischemic cardiomyopathy.

The angiogenic/vasculogenic properties of EPC-EV-derived miRs in silico. As shown in Figure 4, the EPC-EVs-derived miR targets are expressed on angiogenesis- and vasculogenesis-related genes. The majority of the neovascularization phenomenon is coupled with cardiovascular system development and function (Figure 4). Plummder et al. (59) reported that EPC-derived miR-10b and miR-196b overexpression activates VEGF, and the latter enhances breast tumor vasculature. Interestingly, downregulation of miR-10b and miR-196b significantly inhibited tumor angiogenesis in mice, indicating a strong angiogenic potential. miR-126-5p and miR-126-3p overexpression promoted EPC migration and tube-like structure formation in ischemic cardiomyopathy patients in vitro (57). Moreover, transplantation of miR-126-3p-overexpressing EPCs into a rat model of MI showed left ventricular hemodynamic functions along with histological improvements (57). Mathiyalagan et al. (23) also demonstrated that silencing miR-126-3p from CD34 cell-derived exosomes abolished their angiogenic activity and beneficial function both in vitro and in vivo. Furthermore, injection of CD34 cell-derived exosomes increased miR-126-3p levels in mouse ischemic limbs but did not affect the endogenous synthesis of miR-126-3p, indicating a direct transfer of functional miR-126-3p to the ischemic tissue (23).

DELIVERY ROUTES OF EPC-EVS

Systemic Infusion vs. Local Injection

Previous cell therapy trials have reported that the efficacy of cell therapy is limited by poor engraftment of cells or that engrafted cells disappear several months after transplantation, suggesting a paracrine-based effect on the tissues. Depending on the disease state and location, EV transplantation routes may differ. Classical intravenous transplantation of EPC-EVs has been widely used in preclinical and clinical studies (12, 67) (Table 2). Several beneficial functions of systemic transplantation are listed, including (i) no requirement for special sophisticated delivery techniques, (ii) the immunomodulatory effect of EPC-EVs, and (iii) option for repetitive transplantation that is advantageous for local delivery. Sometimes, the desired results cannot be obtained after one injection of EVs; consequently, repetitive systemic transplantation via the vein is needed, whereas in several diseases, local transplantation is not allowed for this technique. Recently, Yi et al. (27) reviewed 29 publications on the route of administration in preclinical studies and showed that the intravenous route was selected in ~80% of exosome injections, and the remaining exosome delivery routes were intraperitoneal, oral, or local. For instance, an ongoing phase one clinical trial (NCT04327635) on safety evaluation of intracoronary infusion of EV in patients with acute myocardial infarction performs within 20 min after stent placement or post-dilation (whichever is last) (Table 2). This kind of delivery methodology is widely used in previous/also current cell transplantation trials into stent placement or post-dilation vessels to enhance the treatment of damaged organs. Another completed clinical trial (NCT04134676) primary outcome revealed that stem cell-conditioned media-derived EVs therapeutic potential is promising in terms of chronic ulcer size reduction, edema decrease, and presence of granulation signs (Table 2). These
macroscopic findings were reported 2 weeks after local delivery of EVs via gel.

In most cases, intravenously transplanted EVs accumulate in the liver, lung, spleen, and kidney (27). For target organ delivery, it has been shown that the local tissue inflammatory environment and activation of receptors and ligands (adhesion molecules) play essential roles in EV uptake. This information is valuable for in vivo biodistribution of exosomes and the control of dose and potential side effects.

LOCAL SUSTAINED DELIVERY SYSTEM

To achieve better results, a targeted delivery system with sustained release to damaged organs may be required. Chen et al. (33) demonstrated that the injection of EPC-EVs incorporated with shear-thinning gel into the border zone of myocardial infarction improved the hemodynamic function of the heart. The average steady EPC-EV release from the gel continued for over 21 days. This EV delivery strategy may enhance EV retention by damaged tissue owing to the sustained release and has potential for active use in trophic ulcer treatment.

MECHANISM OF UPTAKE AND ACTION OF EPC-EVS

The mechanism of EV internalization into recipient or acceptor cells is crucial in terms of intercellular communication. Several EV internalization mechanisms have been presented previously in the scientific literature, such as direct uptake followed by fusion, phagocytosis, and macropinocytosis by the recipient cell membrane (25). Indirect EV uptake mechanisms are sophisticated and work through other pathways, such as the clathrin-dependent and clathrin-independent pathways and lipid raft-mediated, caveolin-mediated, and cell surface protein-mediated endocytosis (24, 25, 68). In addition, recent reports revealed that tissue microenvironment pH is a crucial factor for EV uptake and secretion (69); for instance, in a rodent myocardial ischemia injury model, MSC-EVs internalization into ischemic cardiomyocytes was enhanced compared to that in the non-ischemic counterparts, indicating a low pH condition as the likely mechanism (69, 70). Another factor that is common for the preferential accumulation of EPCs and hematopoietic cells in ischemic tissue is the SDF-1/CXCR4 system (71–73). Recently, Viñas et al. (14) showed that CXCR4/SDF-1α interaction plays an essential role in EPC-derived exosome uptake in a mouse acute kidney ischemia-reperfusion injury model. Interestingly, EPC-EVs selectively targeted the ischemic kidney tissues. Hence, transplanted EPC-EVs were detected 30 min to 4 h after reperfusion only within the proximal tubules, glomeruli, and endothelial cells. However, this preferential internalization into the ischemic kidney was interrupted when exosomes were pre-incubated with the CXCR4 inhibitor plerixafor, suggesting CXCR4/SDF-1α-dependent EPC-EV uptake in ischemic tissues. Taken together, EPC-EVs internalize to the target cells of the CXCR4/SDF-1α system under ischemic conditions, similar to EPCs, although other EPC-EV internalization mechanisms are essential for non-ischemic diseases.

LONG-TERM PRESERVATION AND STORAGE OF EVS

One of the major challenges for the prolonged clinical applicability of EVs is the establishment of proper and
reproducible preservation and storage conditions without compromising their therapeutic potential. Several studies have shown that different methods of storage, chemical compounds, and temperature range optimization are crucial before translation to the clinic (74–76). Recently, Wu et al. (77) evaluated the effect of storage temperature by storing EVs at 4 °C, −20 °C, and −80 °C for up to 28 days and comparing them to fresh EVs. In comparison to fresh EVs, 1 month of storage at 4 °C and −20 °C changed the size distribution, decreased the quantity and content, and affected cellular uptake and biodistribution of EVs; however, storage at −80 °C did not show such effects. The authors concluded that storage at 4 °C or −20 °C is suitable for short-term preservation, whereas −80 °C would be preferable for long-term preservation of EVs for therapeutic applications (77). Jin et al. (78) reported that EVs are stable under the conditions of 4 °C (for 24, 72, and 168 h), at room temperature (for 6, 12, 24, and 48 h), and repeated freeze-thaw (from one to five times).

Moreover, the assessment of DNA content and functionality in EVs was stable in a changing environment over repeated freeze-thaw cycles (78). Freeze-drying or lyophilization seems to be the most reliable method for preserving EVs (76). The common stabilizers used in lyophilization are disaccharides such as glucose, lactose, sucrose, and trehalose. A comparative study of EV storage at 4 °C or −80 °C and freeze-drying showed that lyophilization preserves size and enzyme activity which are indicators of EV stability (79). In summary, for long-term EV storage, preferable conditions are deep freezing, such as at −80 °C or below, whereas 4 °C may be acceptable for short-term use. For advanced EV applications, it is preferable to store EV using lyophilization methods to optimize the biological function and therapeutic potential of EVs.

FUTURE PERSPECTIVES AND CONCLUSION

Intensive research on endothelial progenitor cells and translation to the clinic for various cardiovascular ischemic diseases has increased our understanding of their therapeutic mechanisms (e.g., paracrine mechanism-based action) and biological function (80–82). EPC-EVs may be considered as a primary candidate for use against certain ischemic diseases, owing to their strong angiogenic, anti-fibrosis, and immunomodulatory properties (12, 20, 21, 23, 33, 57, 59, 80, 82–86) and safety in clinical settings (Table 2). However, there are hurdles to overcome before EPC-EVs can be applied as therapies such as standardization of classification and nomenclature of EPCs and focusing on the question of which EPCs should be used (9, 87). In addition, depending on the origin, such as tissue-derived or circulating EPCs, EPC-EVs cargo may contain/comprise various genetic materials that could influence the clinical outcome and should be carefully considered before therapy. Another aspect that needs to be addressed is EPC culturing conditions, including the effect of culture media, ischemia preconditioning, and composition of EVs, all of which must be investigated precisely using large animal disease models. The development of optimized and scalable isolation of pure, clinical-grade EPC-EVs for off-the-shelf therapy will increase their significance. To date, most EV-based studies have used intravenous bolus injection methods, although the choice of the EV delivery route depends on the location of the disease.

Nevertheless, completed and ongoing clinical trials (Table 2), as well as numerous preclinical studies (38, 42, 44, 45, 86, 88), indicate that EPC-EV therapy is feasible and that EVs are safe and well-tolerated.

AUTHOR CONTRIBUTIONS

AS and AK contributed to the literature research and data collection, and were involved in the draft of the manuscript. AK contributed to figure generation and bioinformatic analyses. AS, SK, and TA contributed to the coordination and design of the review and writing of the final draft of the manuscript. All authors have read and approved the final manuscript.

FUNDING

This research was supported by JSPS KAKENHI funding (grant no. 20K17163 to AS).

REFERENCES

1. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. (1997) 275:964–6. doi: 10.1126/science.275.5302.964
2. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki G. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. (2002) 360:227–35. doi: 10.1016/S0140-6736(02)09670-8
3. Lin Y, Weidorf JD, Solovey A, Hebbel PR. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. (2000) 105:71–7. doi: 10.1172/JCI8071
4. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood. (2004) 104:2752–60. doi: 10.1182/blood-2004-04-1396
5. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. (1999) 85:221–8. doi: 10.1161/01.RES.85.3.221
6. Bailey AS, Jiang S, Afentoulis M, Baumann CI, Schroeder AD, Olson SB, et al. Transplanted adult hematopoietic stem cells differentiate into functional endothelial cells. Blood. (2004) 103:13–9. doi: 10.1182/blood-2003-05-1684
7. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. (2005) 11:261–2. doi: 10.1038/nm1200
8. Göthert JR, Gustin SE, van Eekelen JM, Schmidt U, Hall MA, Jane SM, et al. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood. (2004) 104: 1769–77. doi: 10.1182/blood-2003-11-3952
23. Mathiyalagan P, Liang Y, Kim D, Misener S, Thorne T, Kamide M, Martin-Jaular L, Lavieu G, Théry C. Specificities of two types of endothelial progenitor cells and their different contributions to neovascularization. Arterioscler Thromb Vasc Biol. (2004) 24: 288–93. doi: 10.1161/01.ATV.0000114236.77009.06

24. O’Neill CL, Guduric-Fuchs J, Chambers SE, O’Doherty M, Bottazzi B, Stitt AW, et al. Endothelial cell-derived pentraxin 3 limits the vasoparative therapeutic potential of circulating angiogenic cells. Cardiovasc Res. (2016) 112:677–88. doi: 10.1093/cvrr/cwv209

25. Ranghino A, Cantaluppi V, Grange C, Vitillo L, Fop F, Biancone L, Deregibus MC, et al. Endothelial progenitor cell-derived microvesicles improve neovascularization in a murine model of hindlimb ischemia. Int J Immunopathol Pharmacol. (2012) 25:75–85. doi: 10.23736/S0396-6338.2012.005110

26. Cantaluppi V, Gatti S, Medica D, Figliolini F, Bruno S, Deregibus MC, et al. Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int. (2012) 82: 412–27. doi: 10.1038/ki.2012.105

27. Viñas JL, Spence M, Gutsol A, Knoll W, Burger D, Zimpelmann J, et al. Receptor-ligand interaction mediates targeting of endothelial colony forming cell-derived exosomes to the kidney after ischemic injury. Sci Rep. (2018) 8: 1–12. doi: 10.1038/s41598-018-34557-7

28. Viñas JL, Burger D, Zimpelmann J, Haneef R, Knoll W, Campbell P, et al. Transfer of microRNA-486-5p from human endothelial colony forming cell-derived exosomes reduces ischemic kidney injury. Kidney Int. (2016) 90:1238–50. doi: 10.1016/j.kint.2016.07.015

29. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andritsotitohaina ME, et al. Angiogenic mechanisms of human CD34(+) stem cells mediate their proangiogenic paracrine activity. Circ Res. (2011) 109:724–8. doi: 10.1161/CIRCRESAHA.111.253286

30. Bitzer M, Ben-Dov IZ, Thum T. Microparticles and microRNAs of endothelial progenitor cells ameliorate acute kidney injury. Kidney Int. (2012) 82:375–7. doi: 10.1038/ki.2012.152

31. Mathiyalagan P, Liang Y, Kim D, Misener S, Thorne T, Kamide CE, et al. Angiogenic mechanisms of human CD34(+) stem cell exosomes in the repair of ischemic hindlimb. Circ Res. (2017) 120:1466–76. doi: 10.1161/CIRCRESAHA.116.310557

32. Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. (2019) 21:9–17. doi: 10.1038/s41556-018-0250-9

33. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. J Extravas Vesicles. (2014) 3. doi: 10.3402/jev.v3.24641

34. Tovirho V, Morales S, López-Martín S, Cardenes B, Cabanas C, Váñez-Mó M. Development of a quantitative method to measure EV uptake. Sci Rep. (2019) 9:10522. doi: 10.1038/s41598-019-47023-9

35. YiYW, LeeJH, KimS, PackC, HaDH, ParkSR, et al. Advances in Analysis of Biodistribution of Exosomes by Molecular Imaging. Int J Mol Sci. (2020) 21:665. doi: 10.3390/ijms21020665

36. Sanganamuth SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. (2013) 113:810–34. doi: 10.1161/CIRCRESAHA.113.300219

37. Afzal MR, Samanta A, Shah ZI, Jeevanantham V, Abdel-Latif A, Zaburma EK, et al. Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials. Circ Res. (2015) 117:558–75. doi: 10.1161/CIRCRESAHA.114.304792

38. Medina R, O’Neill CL, Sweeney M, Guduric-Fuchs J, Gardiner TA, Simpson DA, et al. Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities. BMC Med Genomics. (2010) 3.18. doi: 10.1186/1755-8794-3-18

39. Liu W, Zhang H, Mai J, Chen Z, Huang T, Wang S, et al. Distinct anti-fibrotic effects of exosomes derived from endothelial colony-forming cells cultured under normoxia and hypoxia. Med Sci Monit. (2018) 24:6187–99. doi: 10.12659/MSM.911306

40. Minami Y, Nakajima T, Ikutomi M, Morita T, Komuro I, Sata M, et al. Angiogenic potential of early and late outgrowth endothelial progenitor cells is dependent on the time of emergence. Int J Cardiol. (2015) 186:305–14. doi: 10.1016/j.ijcard.2015.03.166

41. Chen CW, Wang LL, Zaman S, Gordon J, Arisi MI, Venkataraman CM, et al. Sustained release of endothelial progenitor cell-derived extracellular vesicles from shear-thinning hydrogels improves angiogenesis and promotes function after myocardial infarction. Cardiovasc Res. (2018) 114:1029–40. doi: 10.1093/cvr/cvy067

42. Ong S, Wu JC. Exosomes as potential alternatives to stem cell therapy in mediating cardiac regeneration. Circ Res. (2015) 117:7–9. doi: 10.1161/CIRCRESAHA.113.306593

43. Dellett M, Brown ED, Guduric-Fuchs J, O’Connor A, Stitt AW, Medina R, et al. MicroRNA-containing extracellular vesicles released from endothelial colony-forming cells modulate angiogenesis during ischaemic retinopathy: J Cell Mol Med. (2017) 21:3405–19. doi: 10.1111/jcm.12351

44. Editorial TL. Life, death, and disability in 2016. Lancet. (2017) 390:1083. doi: 10.1016/S0140-6736(17)32465-0

45. Liu H, Gong Y, Yu C, Sun Y, Li X, Zhao D, et al. Endothelial progenitor cells in cardiovascular diseases: from biomarker to therapeutic agent. Regenerat Med Res. (2013) 1:1–5. doi: 10.1186/2050-490X-1-9

46. Yue Y, Wang C, Benedict C, Huang G, Truongcao M, Roy R, et al. Interleukin-10 deficiency alters endothelial progenitor cell-derived exosome reparative effect on myocardial repair via integrin-linked kinase enrichment. Circ Res. (2020) 126:315–29. doi: 10.1161/CIRCRESAHA.119.315829

47. Mathieu M, Klyachko E, Thorne T, Schultz KM, Millay M, Ito A, et al. Sonic hedgehog-modified human CD34+ cells preserve cardiac function after acute myocardial infarction. Circ Res. (2012) 112:312–21. doi: 10.1161/CIRCRESAHA.112.366015

48. Salybekov AA, Salybekova AK, Pola R, Asahara T. Sonic hedgehog signaling pathway in endothelial progenitor cell biology for vascular medicine. Int J Mol Sci. (2018) 19:3040. doi: 10.3390/ijms19103040

49. Ke X, Yang R, Wu F, Wang X, Liang J, Xu H, et al. Exosomal miR-218-3p/miR-363-3p from endothelial progenitor cells ameliorate myocardial infarction by targeting the p53/MYV signaling pathway. Oxid Med Cell Longevity. (2021) 2021:5529430. doi: 10.1155/2021/5529430

50. Ke X, Yang D, Liang J, Wang X, Wu S, Wang X, et al. Human endothelial progenitor cell-derived exosomes increase proliferation and angiogenesis in cardiac fibroblasts by promoting the mesenchymal-endothelial transition and reducing high mobility group box 1 protein B1 expression. DNA Cell Biol. (2017) 36:1018–28. doi: 10.1089/dna.2017.3836

51. Sushantia A, Grocott MPW, Postle AD, Cusack R. Acute Respiratory Distress Syndrome and Acute Lung Injury. BMJ Publishing Group Limited (2011). doi: 10.1136/primjnl-2011-118598

52. Zhou Y, Li P, Goodwin AJ, Cook JA, Halushka PV, Chang E, et al. Exosomes from endothelial progenitor cells improve outcomes of the lipopolysaccharide-induced acute lung injury. Crit Care. (2019) 23:1–12. doi: 10.1186/s13054-019-2339-3
62. Zhao T, Li J, Chen AF. MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenicity via suppressing silent information regulator 1. Am J Physiol Endocrinol Metab. (2010) 299:E110–6. doi: 10.1152/ajpendo.00192.2010

63. Landskroner-Eiger S, Moneke I, Sessa WC. miRNAs as modulators of angiogenesis. Cold Spring Harbor Perspect Med. (2013) 3:a006643. doi: 10.1101/cshperspect.a006643

45. Wu X, Liu Z, Hu L, Gu W, Zhu L. Exosomes derived from endothelial progenitor cells ameliorate acute lung injury by transferring miR-126. Exp Cell Res. (2018) 370:13–23. doi: 10.1016/j.yexcr.2018.06.003

46. Fan H, Goodwin AJ, Chang E, Zingarelli B, Borg K, Guan S, et al. Endothelial progenitor cells and a stromal cell-derived factor-1α analogue synergistically improve survival in sepsis. Am J Respir Crit Care Med. (2014) 189:1509–19. doi: 10.1164/rccm.201312-2163OC

52. Bates BD, Godbout C, Ramnaraign DJ, Schemitsch EH, Nauth A. microRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. J Cell Mol Med. (2018) 92:449–55. doi: 10.1093/cvr/cvr227

53. Cui Y, Fu S, Sun D, Xing J, Hou T, Wu X. EPC-derived exosomes promote osteoclastogenesis through LncRNA-MALAT1. J Cell Mol Med. (2019) 23:3843–54. doi: 10.1111/jcmm.14228

54. Pang H, Wu X, Fu S, Luo F, Zhang Z, Hou T, et al. Co-culture with endothelial progenitor cells promotes survival, migration, and differentiation of osteoclast precursors. Biochem Biophys Res Comm. (2013) 430:729–34. doi: 10.1016/j.bbrc.2012.11.081

55. Qin Y, Zhang C. Endothelial progenitor cell-derived extracellular vesicles protect from complement-mediated mesangial injury in experimental anti-Thyl.1 glomerulonephritis. Nephrol Dialysis Transplant. (2015) 30:410–22. doi: 10.1093/ndt/gfu364

56. Jia Y, Zhu Y, Qiu S, Xu J, Chai Y. Exosomes secreted by endothelial progenitor cells improve the outcome of a murine model of sepsis. Mol Ther. (2018) 26:1375–84. doi: 10.1038/ymthe.2018.02.020

57. Calmantipilli V, Medica D, Mannari C, Stiaccini G, Figliolini F, Dellepiane S, et al. Endothelial progenitor cell-derived extracellular vesicles protect from complement-mediated mesangial injury in experimental anti-Thyl.1 glomerulonephritis. Nephrol Dialysis Transplant. (2015) 30:410–22. doi: 10.1093/ndt/gfu364

58. Würdinger T, Tannous BA, Saydam O, Skog J, Grau S, Soutschek J, et al. miR-126-3p improves osteogenesis by stimulating angiogenesis. Stem Cells Transl Med. (2017) 6:1730–9. doi: 10.1002/stcm.17-0055

59. Yamanouchi K, Kusano MF, Masuo O, Kawamoto A, Silver M, Murasawa S, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. (2003) 107:1322–8. doi: 10.1161/01.CIR.0000055313.75710.22

60. Pan L, Guo X, Chen Z, You B, Shen J, Xue Y, et al. MiR-150 enhances the repair and indirect immunomodulation. Inflamm Res. (2019) 69:1–9. doi: 10.1007/s00011-019-01299-9

61. Reiner AT, Witwer KW, van Balkom BWM, de Beer J, Brodie C, Corteling J, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. (2009) 284:34211–22. doi: 10.1074/jbc.M109.041152

62. Verdera HC, Gitz-Francois JJ, Schifflers RM, Vader P. Cellular uptake of extracellular vesicles is mediated by clathrin-independent endocytosis and macropinocytosis. J Control Release. (2017) 266:100–8. doi: 10.1016/j.jconrel.2017.09.019

63. Wurdinger T, Tannous BA, Saydam O, Skog J, Grau S, Soutschek J, et al. miR-126-3p improves osteogenesis by stimulating angiogenesis. Stem Cells Transl Med. (2017) 6:1730–9. doi: 10.1002/stcm.17-0055

64. Wu J, Li Y, Hu X, Huang S, Xiang D. Preservation of small extracellular vesicles in serum: ex vivo and in vivo study of exosome traffic in tumor cells. Exp Cell Res. (2013) 73:341–52. doi: 10.1158/0008-5472.CAN-12-0271

65. Verdera HC, Gitz-Francois JJ, Schiffelers RM, Vader P. Cellular uptake of extracellular vesicles is mediated by clathrin-independent endocytosis and macropinocytosis. J Control Release. (2017) 266:100–8. doi: 10.1016/j.jconrel.2017.09.019

50. Cantaluppi V, Medica D, Mannari C, Stiaccini G, Figliolini F, Dellepiane S, et al. Endothelial progenitor cell-derived extracellular vesicles translation to the clinic.
82. Mirotsou M, Jayawardena TM, Schmeckpeper J, Gnecchi M, Dzau VJ. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. *J Mol Cell Cardiol.* (2011) 50:280–9. doi: 10.1016/j.yjmcc.2010.08.005

83. Bruyndonckx L, Hoymans VY, Frederix G, De Guchtenaere A, Franckx H, Vissees DK, et al. Endothelial progenitor cells and endothelial microparticles are independent predictors of endothelial function. *J Pediatr.* (2014) 165:300–5. doi: 10.1016/j.jpeds.2014.04.015

84. Gu S, Zhang W, Chen J, Ma R, Xiao X, Ma X, et al. EPC-derived microvesicles protect cardiomyocytes from Ang II-induced hypertrophy and apoptosis. *PLoS ONE.* (2014) e85396. doi: 10.1371/journal.pone.0085396

85. Hu H, Wang B, Jiang C, Li R, Zhao J. Endothelial progenitor cell-derived exosomes facilitate vascular endothelial cell repair through shuttling miR-21-5p to modulate Thrombospondin-1 expression. *Clin Sci.* (2019) 133:1629–44. doi: 10.1042/CS20190188

86. Li X, Chen C, Wei L, Li Q, Niu X, Xu Y, et al. Exosomes derived from endothelial progenitor cells attenuate vascular repair and accelerate reendothelialization by enhancing endothelial function. *Cytotherapy.* (2016) 18:253–62. doi: 10.1016/j.jcyt.2015.11.009

87. Coumans FAW, Brisson AR, Buzas EI, Dignat-George F, Drees EEE, El-Andaloussi S, et al. Methodological guidelines to study extracellular vesicles. *Circ Res.* (2017) 120:1632–48. doi: 10.1161/CIRCRESAHA.117.309417

88. Zhang J, Chen C, Hu B, Niu X, Liu X, Zhang G, et al. Exosomes derived from human endothelial progenitor cells accelerate cutaneous wound healing by promoting angiogenesis through Erk1/2 signaling. *Int J Biol Sci.* (2016) 12:1472–87. doi: 10.7150/ijbs.15514

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2021 Salybekov, Kunikeyev, Kobayashi and Asahara. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*